SC
PRAX icon

Stephens Consulting’s Praxis Precision Medicines PRAX Stock Holding History

Stephens Consulting’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$379 – 1785
2025
Q1 		$379 Buy
+10
New +$625 ﹤0.01% 1141

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Stephens Consulting's PRAX Position: Q2 2025 in Review

Stephens Consulting sold out of Praxis Precision Medicines (PRAX) in Q2 2025, closing a stake of 10 shares — an estimated $379 sold.

Stephens Consulting first reported a position in PRAX in Q1 2025 and held it in 1 quarter. The position peaked at $379 in Q1 2025. 143 funds tracked by Wall St. Rank hold PRAX as of Q2 2025.

  • Stephens Consulting reported no remaining Praxis Precision Medicines position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 10 Praxis Precision Medicines shares in Q2 2025, an estimated $379.
  • Stephens Consulting first reported a position in Praxis Precision Medicines in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Praxis Precision Medicines position peaked at $379 in Q1 2025.
  • 143 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.